Amgen and Adaptive Biotechnologies Collaborate to Develop Therapies Targeting COVID-19

Amgen and Adaptive Biotechnologies Collaborate to Develop Therapies Targeting COVID-19

Shots:

  • The collaboration leverages Adaptive’s immune medicine platform for the identification of virus-neutralizing Abs with Amgen’s proficiency in immunology and novel Abs development
  • Adaptive extends immune medicine platform to discover Abs from recovered COVID-19 patients, which enables the company to identify Abs from survivors of COVID-19 to select those that neutralize SARS-CoV-2
  • Amgen will leverage its expertise to select, develop and manufacture Abs designed to bind and neutralize SARS-CoV-2. Additionally, both the companies have signed an MoU enabling the partners to commence the work immediately and are planning to execute a collaboration and license agreement

Click here ­to­ read full press release/ article | Ref: Amgen | Image: Biospace